Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...
The weight loss medication tirzepatide (Mounjaro and Zepbound) is no longer in shortage, according to the FDA. Access to ...
Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
A new evidence review says that coffee and tea consumption are linked to a lower risk of cancers of the mouth, throat, and head and neck, per the results published in the journal Cancer.